longfellow95 Tuesday, 02/05/19 03:23:15 PM Re: None Post # of 323896 BMY really don't seem to have a clue... They're running a new randomized open-label P2 in recurrent GBM. Two arms. Arm 1. Nivo plus standard dose Bev. Arm 2. Nivo plus reduced dose Bev Primary outcome: OS12. Secondary outcome: OS. Measured up to 3yrs. https://clinicaltrials.gov/ct2/show/study/NCT03452579#contacts What do they hope to learn? I expect the only things they will learn are that Bev caps survival from recurrence at 10 months max with considerable toxicity, and Nivo reduces PFS compared to giving nothing, but adds toxicity. As was previously demonstrated in Checkmate 143, a P3 no less, when Nivo reduced PFS to 1.5 months... https://academic.oup.com/neuro-oncology/article/19/suppl_3/iii21/3743874 Pity the patients.